{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T05:04:13Z","timestamp":1710738253050},"reference-count":65,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            We examine the impact of the new risk information about a surgical device on surgery and patient outcomes for hysterectomy in the inpatient setting.\n            <jats:bold>Methods:<\/jats:bold>\n            We utilize a difference-in-differences approach to assess the impact of new risk information on patient outcomes in the inpatient setting between 2009 and 2014. The inpatient data come from a nationally representative sample of hospitalizations in the USA. We use the likelihood of laparoscopic surgery, measures of resource use and surgical complications as outcome variables.\n            <jats:bold>Results:<\/jats:bold>\n            We estimate a three-percentage point decrease in the likelihood of receiving laparoscopic hysterectomy, a one-percentage point increase in the likelihood of experiencing a surgical complication and no impact on resource use, relative to pre-existing means.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Our findings show that there was movement away from laparoscopic surgery in the months following the dissemination of new risk information. These changes had limited effect on patient outcomes.\n          <\/jats:p>","DOI":"10.2217\/cer-2019-0093","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T10:13:18Z","timestamp":1576491198000},"page":"53-65","source":"Crossref","is-referenced-by-count":2,"title":["The impact of recent power morcellator risk information on inpatient surgery and patient outcomes"],"prefix":"10.57264","volume":"9","author":[{"given":"Ehren","family":"Schuttringer","sequence":"first","affiliation":[{"name":"Food &amp; Drug Administration Office of the Commissioner, 10903 New Hampshire Ave, Silver Spring,\u00a0Maryland, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinidad","family":"Beleche","sequence":"additional","affiliation":[{"name":"Food &amp; Drug Administration Office of the Commissioner, 10903 New Hampshire Ave, Silver Spring,\u00a0Maryland, MD 20993, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in Black and White Women: ultrasound evidence","volume":"188","author":"Baird DD","year":"2003","unstructured":"Baird DD , Dunson DB , Hill MC , Cousins D , Schectman JM . High cumulative incidence of uterine leiomyoma in Black and White Women: ultrasound evidence. Am. J. Obstet. Gynecol. 188, 100\u2013107 (2003).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2217\/CER.14.32"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"211.e211","DOI":"10.1016\/j.ajog.2011.12.002","article-title":"The estimated annual cost of uterine leiomyomata in the United States","volume":"206","author":"Cardozo ER","year":"2012","unstructured":"Cardozo ER , Clark AD , Banks NK , Henne MB , Stegmann BJ , Segars JH . The estimated annual cost of uterine leiomyomata in the United States. Am. J. Obstet. Gynecol. 206, 211.e211\u2013211.e219 (2012).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"e_1_3_3_6_2","unstructured":"NIH. Uterine fibroids. NIH fact sheets (2010). https:\/\/report.nih.gov\/NIHfactsheets\/ViewFactSheet.aspx?csid=50"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bpobgyn.2015.11.016","article-title":"Role of medical management for uterine leiomyomas","volume":"34","author":"Kashani BN","year":"2016","unstructured":"Kashani BN , Centini G , Morelli SS , Weiss G , Petraglia F . Role of medical management for uterine leiomyomas. Best Pract. Res. Clin. Obstet. Gynaecol. 34, 85\u2013103 (2016).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"e_1_3_3_8_2","unstructured":"The American College of Obstetricians and Gynecologists. Uterine fibroids FAQ074 (2011). https:\/\/www.acog.org\/~\/media\/For%20Patients\/faq074.pdf?dmc=1."},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/jama.2016.9432","article-title":"Trends in use and outcomes of women undergoing hysterectomy with electric power morcellation","volume":"316","author":"Wright JD","year":"2016","unstructured":"Wright JD , Chen L , Burke WM Trends in use and outcomes of women undergoing hysterectomy with electric power morcellation. JAMA 316, 877\u2013878 (2016).","journal-title":"JAMA"},{"key":"e_1_3_3_10_2","unstructured":"Food and Drug Administration. Laparscopic power morcellators (2018). https:\/\/www.fda.gov\/medical-devices\/surgery-devices\/laparoscopic-power-morcellators."},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00404-015-3664-7","article-title":"Is open surgery the solution to avoid morcellation of uterine sarcomas? A systematic literature review on the effect of tumor morcellation and surgical techniques","volume":"292","author":"Ebner F","year":"2015","unstructured":"Ebner F , Friedl TWP , Scholz C Is open surgery the solution to avoid morcellation of uterine sarcomas? A systematic literature review on the effect of tumor morcellation and surgical techniques. Arch. Gynecol. Obstet. 292, 499\u2013506 (2015).","journal-title":"Arch. Gynecol. Obstet."},{"key":"e_1_3_3_12_2","unstructured":"American Cancer Society. What is uterine sarcoma? (2019). https:\/\/www.cancer.org\/cancer\/uterine-sarcoma\/about\/what-is-uterine-sarcoma.html."},{"issue":"6","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/IGC.0000000000000940","article-title":"Characterization and preoperative risk analysis of leiomyosarcomas at a high-volume tertiary care center","volume":"27","author":"Peters A","year":"2017","unstructured":"Peters A , Sadecky AM , Winger DG Characterization and preoperative risk analysis of leiomyosarcomas at a high-volume tertiary care center. Int. J. Gynecol. Cancer 27(6), 1183\u20131190 (2017).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"e50058","DOI":"10.1371\/journal.pone.0050058","article-title":"Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms","volume":"7","author":"Seidman MA","year":"2012","unstructured":"Seidman MA , Oduyebo T , Muto MG , Crum CP , Nucci MR , Quade BJ . Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS ONE 7, e50058 (2012).","journal-title":"PLoS ONE"},{"key":"e_1_3_3_15_2","unstructured":"The United States Food and Drug Administration. FDA updated assessment of the use of laparoscopic power morcellators to treat uterine fibroids (2017). https:\/\/www.fda.gov\/media\/109018\/download"},{"key":"e_1_3_3_16_2","first-page":"e238","article-title":"Uterine morcellation for presumed leiomyomas. ACOG Committee Opinion Number 770","volume":"133","author":"American College of Obstetricians and Gynecologists","year":"2019","unstructured":"American College of Obstetricians and Gynecologists. Uterine morcellation for presumed leiomyomas. ACOG Committee Opinion Number 770. Obstetr. Gynecol. 133, e238\u2013e248 (2019).","journal-title":"Obstetr. Gynecol."},{"key":"e_1_3_3_17_2","article-title":"Management of uterine fibroids","author":"Hartmann KE","year":"2017","unstructured":"Hartmann KE , Fonnesbeck C , Surawicz T Management of uterine fibroids. Comparative Effectiveness Review Number 195 (AHRQ Publication No. 17(18)-EHC028-EF), (2017).","journal-title":"Comparative Effectiveness Review Number 195"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00404-015-3696-z","article-title":"Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH)","volume":"292","author":"Bojahr B","year":"2015","unstructured":"Bojahr B , Dewilde RL , Tchartchian G . Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH). Arch. Gynecol. Obstet. 292, 665\u2013672 (2015).","journal-title":"Arch. Gynecol. Obstet."},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10397-015-0894-4","article-title":"The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis","volume":"12","author":"Pritts EA","year":"2015","unstructured":"Pritts EA , Vanness DJ , Berek JS The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecol. Surg. 12, 165\u2013177 (2015).","journal-title":"Gynecol. Surg."},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/AOG.0000000000001242","article-title":"Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications","volume":"127","author":"Kho KA","year":"2016","unstructured":"Kho KA , Lin K , Hechanova M , Richardson DL . Risk of occult uterine sarcoma in women undergoing hysterectomy for benign indications. Obstet. Gynecol. 127, 468\u2013473 (2016).","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_3_21_2","first-page":"39.e31","article-title":"Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectormy","author":"Desai VB","year":"2019","unstructured":"Desai VB , Wright JD , Gross CP Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectormy. Am. J. Obstet. Gynecol. 39.e31\u201339.e14 (2019).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"e_1_3_3_22_2","article-title":"Doctors eye cancer risk in uterine procedure","author":"Levitz J","year":"2013","unstructured":"Levitz J . Doctors eye cancer risk in uterine procedure. The Wall Street Journal (2013). https:\/\/www.wsj.com\/articles\/doctors-eye-cancer-risk-in-uterine-procedure-1387328455","journal-title":"The Wall Street Journal"},{"key":"e_1_3_3_23_2","article-title":"Fibroid surgery puts doctor fighting cancer diagnosis in spotlight","author":"Levitz J","year":"2013","unstructured":"Levitz J . Fibroid surgery puts doctor fighting cancer diagnosis in spotlight. The Wall Street Journal (2013). https:\/\/www.wsj.com\/articles\/fibroid-surgery-puts-doctor-fighting-cancer-diagnosis-in-spotlight-1387457121","journal-title":"The Wall Street Journal"},{"key":"e_1_3_3_24_2","unstructured":"The United States Food and Drug Administration. Laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication (2014). https:\/\/wayback.archive-it.org\/7993\/20170406071822\/https:\/\/www.fda.gov\/MedicalDevices\/Safety\/AlertsandNotices\/ucm393576.htm"},{"key":"e_1_3_3_25_2","unstructured":"The United States Food and Drug Administration. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids (2014). https:\/\/www.fda.gov\/media\/88703\/download"},{"key":"e_1_3_3_26_2","unstructured":"The United States Food and Drug Administration. Updated laparoscopic uterine power morcellation in hysterectomy and myomectomy: FDA safety communication (2014). https:\/\/wayback.archive-it.org\/7993\/20170404182209\/https:\/www.fda.gov\/MedicalDevices\/Safety\/AlertsandNotices\/ucm424443.htm"},{"key":"e_1_3_3_27_2","unstructured":"The United States Food and Drug Administration. Immediately in effect guidance document: product labeling for laparoscopic power morcellators. guidance for industry and food and drug administration staff (2014). https:\/\/www.fda.gov\/media\/90012\/download"},{"key":"e_1_3_3_28_2","article-title":"Johnson & Johnson Pulls hysterectomy device from hospitals","author":"Kamp J","year":"2014","unstructured":"Kamp J , Levitz J . Johnson & Johnson Pulls hysterectomy device from hospitals. The Wall Street Journal (2014). https:\/\/www.wsj.com\/articles\/johnson-johnson-to-call-for-voluntary-return-of-morcellators-1406754350","journal-title":"The Wall Street Journal"},{"key":"e_1_3_3_29_2","article-title":"Hospital chain HCA prohibits power morcellation for uterine fibroids","author":"Kamp J","year":"2014","unstructured":"Kamp J . Hospital chain HCA prohibits power morcellation for uterine fibroids. The Wall Street Journal (2014). https:\/\/www.wsj.com\/articles\/hospital-chain-hca-prohibits-power-morcellation-for-uterine-fibroids-1416948061","journal-title":"The Wall Street Journal"},{"key":"e_1_3_3_30_2","article-title":"Philadelphia hospital restricts \u2018morcellation\u2019 procedure","author":"Kamp J","year":"2014","unstructured":"Kamp J , Levitz J . Philadelphia hospital restricts \u2018morcellation\u2019 procedure. The Wall Street Journal (2014). https:\/\/www.wsj.com\/articles\/no-headline-available-1392904045","journal-title":"The Wall Street Journal"},{"key":"e_1_3_3_31_2","article-title":"More health insurers take action to curb morcellator use","author":"Kamp J","year":"2015","unstructured":"Kamp J . More health insurers take action to curb morcellator use. The Wall Street Journal (2015). https:\/\/www.wsj.com\/articles\/more-health-insurers-take-action-to-limit-morcellator-use-1428009386","journal-title":"The Wall Street Journal"},{"key":"e_1_3_3_32_2","article-title":"Aetna to stop covering routine use of power morcellator","author":"Kamp J","year":"2015","unstructured":"Kamp J . Aetna to stop covering routine use of power morcellator. The Wall Street Journal (2015). https:\/\/www.wsj.com\/articles\/aetna-to-stop-covering-routine-use-of-power-morcellator-1430838666","journal-title":"The Wall Street Journal"},{"key":"e_1_3_3_33_2","article-title":"Biggest U.S. Health insurer tightens rules on hysterectomy coverage","author":"Levitz J","year":"2015","unstructured":"Levitz J , Kamp J . Biggest U.S. Health insurer tightens rules on hysterectomy coverage. The Wall Street Journal (2015). https:\/\/www.wsj.com\/articles\/biggest-u-s-health-insurer-tightens-rules-on-hysterectomy-coverage-1424990877","journal-title":"The Wall Street Journal"},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/AOG.0000000000001111","article-title":"Association of the U.S. Food and Drug Administration morcellation warning with rates of minimally invasive hysterectomy and myomectomy","volume":"126","author":"Barron KI","year":"2015","unstructured":"Barron KI , Richard T , Robinson PS , Lamvu G . Association of the U.S. Food and Drug Administration morcellation warning with rates of minimally invasive hysterectomy and myomectomy. Obstet. Gynecol. 126, 1174\u20131180 (2015).","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"98e91","DOI":"10.1016\/j.ajog.2015.08.047","article-title":"Practice Patterns and postoperative complications before and After US Food and Drug Administration Safety communication on power morcellation","volume":"214","author":"Harris JA","year":"2016","unstructured":"Harris JA , Swenson CW , Uppal S Practice Patterns and postoperative complications before and After US Food and Drug Administration Safety communication on power morcellation. Am. J. Obstet. Gynecol. 214, 98e91\u201398e13 (2016).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"e_1_3_3_36_2","doi-asserted-by":"crossref","first-page":"e180141","DOI":"10.1001\/jamasurg.2018.0141","article-title":"Practice patterns and complications of benign hysterectomy following the FDA statement Warning against the use of power morcellation","volume":"153","author":"Multinu F","year":"2018","unstructured":"Multinu F , Casarin J , Hanson KT Practice patterns and complications of benign hysterectomy following the FDA statement Warning against the use of power morcellation. JAMA Surg. 153, e180141 (2018).","journal-title":"JAMA Surg."},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/AOG.0000000000002058","article-title":"Trends in mode of hysterectomy after the U.S. Food and Drug Administration power morcellation advisory","volume":"129","author":"Ottarsdottir H","year":"2017","unstructured":"Ottarsdottir H , Cohen SL , Cox M , Vitonis A , Einarsson JI . Trends in mode of hysterectomy after the U.S. Food and Drug Administration power morcellation advisory. Obstet. Gynecol. 129, 1014\u20131021 (2017).","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_3_38_2","unstructured":"Schoenman\n                            JA Sutton\n                            JP Kintala\n                            S Love\n                            D Maw\n                            R\n                    . The Value of Hospital Discharge Databases. (AHRQ Contract number 282-98-0024 [Task Order Number 5]) (2005). https:\/\/www.hcup-us.ahrq.gov\/reports\/final_report.pdf"},{"issue":"3","key":"e_1_3_3_39_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jmig.2018.08.012","article-title":"Robotic Radical hysterectomy for cervical cancer: a population-based study of adoption and immediate postoperative outcomes in the United States","volume":"26","author":"Piedimonte S","year":"2019","unstructured":"Piedimonte S , Czuzoj-Shulman N , Gotlieb W , Abenhaim HA . Robotic Radical hysterectomy for cervical cancer: a population-based study of adoption and immediate postoperative outcomes in the United States. J. Minim. Invasive Gynecol. 26(3), 551\u2013557 (2019).","journal-title":"J. Minim. Invasive Gynecol."},{"key":"e_1_3_3_40_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jmig.2016.08.830","article-title":"Inpatient laparoscopic hysterectomy in the United States: trends and factors associated with approach selection","volume":"24","author":"Desai VB","year":"2017","unstructured":"Desai VB , Guo XM , Fan L , Wright JD , Xu X . Inpatient laparoscopic hysterectomy in the United States: trends and factors associated with approach selection. J. Minim. Invasive Gynecol. 24, 151\u2013158 (2017).","journal-title":"J. Minim. Invasive Gynecol."},{"key":"e_1_3_3_41_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/AOG.0b013e318299a6cf","article-title":"Nationwide trends in the performance of inpatient hysterectomy in the United States","volume":"122","author":"Wright JD","year":"2013","unstructured":"Wright JD , Herzog TJ , Tsui J Nationwide trends in the performance of inpatient hysterectomy in the United States. Obstet Gynecol 122, 233\u2013241 (2013).","journal-title":"Obstet Gynecol"},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jmig.2014.01.012","article-title":"Trends in the national distribution of laparoscopic hysterectomies from 2003\u20132010","volume":"21","author":"Lee J","year":"2014","unstructured":"Lee J , Jennings K , Borahay MA Trends in the national distribution of laparoscopic hysterectomies from 2003\u20132010. J. Minim. Invasive Gynecol. 21, 656\u2013661 (2014).","journal-title":"J. Minim. Invasive Gynecol."},{"issue":"4","key":"e_1_3_3_43_2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/AOG.0b013e3182a4ee4d","article-title":"Comparison of robotic and laparoscopic hysterectomy for benign gynecologic disease","volume":"122","author":"Rosero EB","year":"2013","unstructured":"Rosero EB , Kho KA , Joshi GP , Giesecke M , Schaffer JI . Comparison of robotic and laparoscopic hysterectomy for benign gynecologic disease. Obstet. Gynecol. 122(4), 778\u2013786 (2013).","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"e_1_3_3_44_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/AOG.0000000000001567","article-title":"Disparities in surgical care among women with endometrial cancer","volume":"128","author":"Mannschreck D","year":"2016","unstructured":"Mannschreck D , Matsuno RK , Moriarty JP Disparities in surgical care among women with endometrial cancer. Obstet. Gynecol. 128(3), 526\u2013534 (2016).","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"e_1_3_3_45_2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/AOG.0b013e3181b9d222","article-title":"Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches","volume":"114","author":"Jacoby VL","year":"2009","unstructured":"Jacoby VL , Autry M , Jacobson G , Domush R , Nakagawa S , Jacoby A . Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches. Obstet. Gynecol. 114(5), 1041\u20131048 (2009).","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_3_46_2","doi-asserted-by":"crossref","first-page":"538.e531","DOI":"10.1016\/j.ajog.2009.11.030","article-title":"Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979\u20132004","volume":"202","author":"Lowder JL","year":"2010","unstructured":"Lowder JL , Oliphant SS , Ghetti C , Burrows LJ , Meyn LA , Balk J . Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979\u20132004. American Journal of Obstetrics & Gynecology 202, 538.e531\u2013538.e539 (2010).","journal-title":"American Journal of Obstetrics & Gynecology"},{"issue":"96","key":"e_1_3_3_47_2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jpubeco.2012.07.003","article-title":"The impact of health care reform on hospital and preventive care: evidence from Massachusetts","author":"Kolstad JT","year":"2012","unstructured":"Kolstad JT , Kowalski AE . The impact of health care reform on hospital and preventive care: evidence from Massachusetts. J. Public Econ. (96), 909\u2013929 (2012).","journal-title":"J. Public Econ."},{"key":"e_1_3_3_48_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson ME","year":"1987","unstructured":"Charlson ME , Pompei P , Ales KL , Mackenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"key":"e_1_3_3_49_2","article-title":"Charlson: Stata Module to Calculate Charlson Index of Comorbidity","author":"Stagg V","year":"2006","unstructured":"Stagg V . Charlson: Stata Module to Calculate Charlson Index of Comorbidity. Statistical Software Components S456719 (2006). https:\/\/ideas.repec.org\/c\/boc\/bocode\/s456719.html","journal-title":"Statistical Software Components S456719"},{"issue":"1","key":"e_1_3_3_50_2","doi-asserted-by":"crossref","first-page":"e2016.00092","DOI":"10.4293\/JSLS.2016.00092","article-title":"To morcellate or not to morcellate: a cross-sectional survey of gynecologic surgeons","volume":"21","author":"Nexhat F","year":"2017","unstructured":"Nexhat F , Apostol R , Greene AD , Pilkinton ML . To morcellate or not to morcellate: a cross-sectional survey of gynecologic surgeons. JSLS 21(1), e2016.00092 (2017).","journal-title":"JSLS"},{"key":"e_1_3_3_51_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jmig.2016.01.019","article-title":"Impact of the 2014 Food and Drug Administration warnings against power morcellation","volume":"23","author":"Lum DA","year":"2016","unstructured":"Lum DA , Sokol ER , Berek JS Impact of the 2014 Food and Drug Administration warnings against power morcellation. J. Minim. Invasive Gynecol. 23, 548\u2013556 (2016).","journal-title":"J. Minim. Invasive Gynecol."},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2014.11.018","article-title":"Incident power morcellation of malignancy: a retrospective cohort study","volume":"136","author":"Graebe K","year":"2015","unstructured":"Graebe K , Garcia-Soto A , Aziz M Incident power morcellation of malignancy: a retrospective cohort study. Gynecol. Oncol. 136, 274\u2013277 (2015).","journal-title":"Gynecol. Oncol."},{"key":"e_1_3_3_53_2","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2017.00015","article-title":"Contained morcellation: review of current methods and future directions","volume":"4","author":"Taylan E","year":"2017","unstructured":"Taylan E , Sahin C , Zeybek B , Akdemir A . Contained morcellation: review of current methods and future directions. Front. Surg. 4 (Article 15), (2017).","journal-title":"Front. Surg."},{"key":"e_1_3_3_54_2","unstructured":"American Cancer Society. Survival rates for uterine sarcoma (2019). https:\/\/www.cancer.org\/cancer\/uterine-sarcoma\/detection-diagnosis-staging\/survival-rates.html."},{"key":"e_1_3_3_55_2","unstructured":"The United States Department of Health and Human Services. Guidelines for regulatory impact analysis: a primer. Office of the assistant secretary for planning and evaluation 2016 (2016). https:\/\/aspe.hhs.gov\/system\/files\/pdf\/242931\/HHS_RIAGuidancePrimer.pdf"},{"key":"e_1_3_3_56_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2013\/863056","article-title":"Utility values for advanced soft tissue sarcoma health states from the general public in the United Kingdom","volume":"2013","author":"Guest JF","year":"2013","unstructured":"Guest JF , Sladkevicius E , Gough N , Linch M , Grimer R . Utility values for advanced soft tissue sarcoma health states from the general public in the United Kingdom. Sarcoma 2013, 9 (2013).","journal-title":"Sarcoma"},{"key":"e_1_3_3_57_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1089\/jwh.2015.5708","article-title":"The clinical and economic benefits of co-testing versus primary HPV testing for cervical cancer screening: a modeling analysis","volume":"25","author":"Felix JC","year":"2016","unstructured":"Felix JC , Lacey MJ , Miller JD , Lenhart GM , Spitzer M , Kulkarni R . The clinical and economic benefits of co-testing versus primary HPV testing for cervical cancer screening: a modeling analysis. J. Women's Health 25, 606\u2013616 (2016).","journal-title":"J. Women's Health"},{"issue":"4","key":"e_1_3_3_58_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of a nationally representative values for the noninstitutionalized US adult population for 7 health-related quality of life scores","volume":"26","author":"Hanmer J","year":"2006","unstructured":"Hanmer J , Lawrence WF , Anderson JP , Kaplan RM , Fryback DG . Report of a nationally representative values for the noninstitutionalized US adult population for 7 health-related quality of life scores. Med. Decis. Making 26(4), 391\u2013400 (2006).","journal-title":"Med. Decis. Making"},{"key":"e_1_3_3_59_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/pop.2014.0148","article-title":"Cost\u2013effectiveness of global endometrial ablation vs hysterectomy for treatment of abnormal uterine bleeding: US commercial and medicaid payer perspectives","volume":"18","author":"Miller JD","year":"2015","unstructured":"Miller JD , Lenhart GM , Bonafede MM , Lukes AS , Laughlin-Tommaso SK . Cost\u2013effectiveness of global endometrial ablation vs hysterectomy for treatment of abnormal uterine bleeding: US commercial and medicaid payer perspectives. Popul. Health Manag. 18, 373\u2013382 (2015).","journal-title":"Popul. Health Manag."},{"issue":"8","key":"e_1_3_3_60_2","first-page":"40","article-title":"Open vs minimally invasive hysterectomy: commercially insured costs and readmissions","volume":"25","author":"Fitch K","year":"2016","unstructured":"Fitch K , Huh W , Bochner A . Open vs minimally invasive hysterectomy: commercially insured costs and readmissions. Manag. Care 25(8), 40\u201347 (2016).","journal-title":"Manag. Care"},{"issue":"4","key":"e_1_3_3_61_2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/AOG.0000000000003181","article-title":"Hysterectomy practice patterns int he postmorcellation Era","volume":"133","author":"Jorgensen EM","year":"2019","unstructured":"Jorgensen EM , Modest AM , Hur H-C , Hacker MR , Awtrey CS . Hysterectomy practice patterns int he postmorcellation Era. Obstet. Gynecol. 133(4), 643\u2013649 (2019).","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_3_62_2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/jamasurg.2016.0804","article-title":"Trends in inpatient and outpatient hysterectomy and oophorectomy among commercially insured women in the United States: 2000\u20132014","volume":"151","author":"Doll KM","year":"2016","unstructured":"Doll KM , Busetzina SB , Robinson W . Trends in inpatient and outpatient hysterectomy and oophorectomy among commercially insured women in the United States: 2000\u20132014. JAMA Surg. 151, 876\u2013877 (2016).","journal-title":"JAMA Surg."},{"key":"e_1_3_3_63_2","article-title":"Trends in hysterectomies and oophorectomies in hospital inpatient and ambulatory settings, 2005\u20132013","author":"Moore BJ","year":"2016","unstructured":"Moore BJ , Steiner CA , Davis PH , Stocks C , Barrett ML . Trends in hysterectomies and oophorectomies in hospital inpatient and ambulatory settings, 2005\u20132013. HCUP Statistical Brief #214 (2016). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK409175\/","journal-title":"HCUP Statistical Brief #214"},{"key":"e_1_3_3_64_2","article-title":"Surgeries in hospital-owned outpatient facilities, 2012","author":"Wier LM","year":"2012","unstructured":"Wier LM , Steiner CA , Owens PL . Surgeries in hospital-owned outpatient facilities, 2012. HCUP Statistical Brief#188. February 2015 (2012).","journal-title":"HCUP Statistical Brief#188. February 2015"},{"key":"e_1_3_3_65_2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/AOG.0000000000002309","article-title":"Change in surgical practice for women with leiomyomas after the U.S. food and drug administration morcellator safety communication","volume":"130","author":"Clark NM","year":"2017","unstructured":"Clark NM , Schembri M , Jacoby VL . Change in surgical practice for women with leiomyomas after the U.S. food and drug administration morcellator safety communication. Obstet. Gynecol. 130, 1057\u20131063 (2017).","journal-title":"Obstet. Gynecol."},{"key":"e_1_3_3_66_2","unstructured":"The United States Food and Drug Administration. Urogynecologic surgical mesh implants April 16 2019 (2019). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-takes-action-protect-womens-health-orders-manufacturers-surgical-mesh-intended-transvaginal"},{"key":"e_1_3_3_67_2","unstructured":"The United States Food and Drug Administration. FDA statement. Statement from FDA Principal Deputy Commissioner Amy Abernethy M.D. Ph.D. and Jeff Shuren M.D. J.D. Director of the FDA's Center for Devices and Radiological Heath on FDA's New Efforts to Protect Women's Health and Help to Ensure the Safety of Breast Implants May 2 2019 (2019). https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-principal-deputy-commissioner-amy-abernethy-md-phd-and-jeff-shuren-md-jd-director-fdas"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2019-0093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:34:04Z","timestamp":1679229244000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2019-0093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.2217\/cer-2019-0093"],"URL":"https:\/\/doi.org\/10.2217\/cer-2019-0093","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}